Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44V6 and microvessel density for prostate cancer

International Journal of Cancer

Volumn 112, Issue 1, 2004, Pages 121-129

  Ekici, Sinan ^a   Cerwinka, Wolfgang H ^a   Duncan, Robert ^a   Gomez, Pablo ^a   Civantos, Francisco ^a   Soloway, Mark S ^a   Lokeshwar, Vinata B ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

CD44v6; HYAL 1; Hyaluronic acid; Hyaluronidase; Microvessel density; Prognostic indicator; Prostate cancer

Indexed keywords

CD34 IMMUNOGLOBULIN G ANTIBODY; CD44V6 ANTIGEN; CD44V6 IMMUNOGLOBULIN G ANTIBODY; CELL SURFACE RECEPTOR; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; HYALURONIC ACID; HYALURONIC ACID BINDING PROTEIN; HYALURONIDASE; HYALURONIDASE IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MARKER; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; BIOTINYLATION; CANCER LOCALIZATION; CANCER PATIENT; CHEMICAL ANALYSIS; CLASSIFICATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DENSITY; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MICROVASCULATURE; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; PREDICTION; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEMINAL VESICLE; SENSITIVITY AND SPECIFICITY; STAINING; TUMOR CELL;

ANTIGENS, CD44; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; IMMUNOENZYME TECHNIQUES; MALE; MICROCIRCULATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 4544317211     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20368     Document Type: Article

References (59)

1. Khan MA, Han M, Partin AW, Epstein JI, Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 2003;62:86-92.
2. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
3. Palisaar RJ, Graefen M, Karakiewicz PI, Hammerer PG, Huland E, Haese A, Fernandez S, Erbersdobler A, Henke RP, Huland H. Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer. Eur Urol 2002;41:155-61.
4. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
5. Neulander EZ, Soloway MS. Failure after radical prostatectomy. Urology 2003;61:30-6.
6. Symon Z, Griffith KA, McLaughlin PW, Sullivan M, Sandler HM. Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformai therapy. Int J Radiat Oncol Biol Phys 2003;57:384-90.
7. Syed S, Petrylak DP, Thompson IM. Management of high-risk localized prostate cancer: the integration of local and systemic therapy approaches. Urol Oncol 2003;21:235-43.
8. Moul JW. Variables in predicting survival based on treating "PSA-only" relapse. Urol Oncol 2003;21:292-304.
9. Swindle PW, Kattan MW, Scardino PT. Markers and meaning of primary treatment failure. Urol Clin North Am 2003;30:377-401.
10. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:119-25.
11. Pettaway CA. Prognostic markers in clinically localized prostate cancer. Tech Urol 1998;4:35-42.
12. Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, Duncan RC, Lokeshwar VB. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HY AL-1) for prostate cancer. Cancer Res 2003;63:2638-44.
13. Tammi MI, Day AJ, Turley EA. Hyaluronan and homeostasis: a balancing act. J Biol Chem 2002;277:4581-4.
14. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002;277:4589-92.
15. Setälä LP, Tammi MI, Tammi RH, Eskelinen MJ, Lipponen PK, Ågren UM, Parkkinen J, Alhava EM, Kosma V-M. Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br J Cancer 1999;79:1133-8.
16. Auvinen P, Tammi R, Parkkinen J, Tammi M, Ågren U, Johansson R, Hirvikoski P, Eskelinen M, Kosma V-M. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000;156:529-36.
17. Knudson W. Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am J Pathol 1996;148:1721-6.
18. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P, Ågren U, Alhava E, Kosma V-M. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 1998;58:342-7.
19. Lipponen P, Aaltomaa S, Tammi R, Tammi M, Ågren U, Kosma V-M. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer 2001;37: 849-56.
20. Lokeshwar VB, Öbek C, Pham HT, Wei D, Young MJ, Duncan RC, Soloway MS, Block NL. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 2000;163:348-56.
21. Hautmann SH, Lokeshwar VB, Schroeder GL, Civantos F, Duncan RC, Gnann R, Friedrich MG, Soloway MS. Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer. J Urol 2001;165:2068-74.
22. Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD, Block NL, Nadji M, Lokeshwar BL. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL-1 hyaluronidase in prostate cancer. J Biol Chem 2001;276:11922-32.
23. Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001;20:499-508.
24. Franzmann EJ, Schroeder GL, Goodwin WJ, Weed DT, Fisher P, Lokeshwar VB. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL-1) in head and neck tumors. Int J Cancer 2003;106:438-45.
25. West DC, Hampson IN, Arnold F, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985;228:1324-6.
26. Lokeshwar VB, Selzer MG. Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells. J Biol Chem 2000;275:27641-9.
27. Pham HT, Block NL, Lokeshwar VB. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res 1997;57:778-83.
28. Kumar S, West DC, Ponting JM, Gattamaneni HR. Sera of children with renal tumours contain low-molecular-mass hyaluronic acid. Int J Cancer 1989;44:445-8.
29. Lesley J, Hascall VC, Tammi M, Hyman R. Hyaluronan binding by cell surface CD44. J Biol Chem 2000;275:26967-75.
30. Cichy J, Pure E. The liberation of CD44. J Cell Biol 2003;161:839-43.
31. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 2002;39:527-79.
32. Lokeshwar VB, Fregien N, Bourguignon LY. Ankyrin-binding domain of CD44(GP85) is required for the expression of hyaluronic acid-mediated adhesion function. J Cell Biol 1994;126:1099-109.
33. Lokeshwar VB, Iida N, Bourguignon LY. The cell adhesion molecule, GP116, is a new CD44 variant (ex 14/v 10) involved in hyaluronic acid binding and endothelial cell proliferation. J Biol Chem 1996;271: 23853-64.
34. Lokeshwar BL, Lokeshwar VB, Block NL. Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. Anticancer Res 1995;15:1191-8.
35. Welsh CF, Zhu D, Bourguignon LY. Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells. J Cell Physiol 1995;164:605-12.
36. Iczkowski KA, Bai S, Pantazis CG. Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level. Anticancer Res 2003;23:3129-40.
37. Gao AC, Lou W, Sleeman JP, Isaacs JT. Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res 1998;58:2350-2.
38. Ekici S, Ayhan A, Kendi S, Özen H. Determination of prognosis in patients with prostate cancer treated with radical prostatectomy: prognostic value of CD44v6 score. J Urol 2002;167:2037-41.
39. Aaltomaa S, Lipponen P, Ala-Opas M, Kosma V-M. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur Urol 2001;39:138-44.
40. Sato Y. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. Int J Clin Oncol 2003;8:200-6.
41. Sullivan DC, Bicknell R. New molecular pathways in angiogenesis. Br J Cancer 2003;89:228-31.
42. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001;86:23-33.
43. Sauer G, Deissler H. Angiogenesis: prognostic and therapeutic implications in gynecologic and breast malignancies. Curr Opin Obstet Gynecol 2003;15:45-9.
44. Goddard JC, Sutton CD, Furness PN, O'Byrne KJ, Kockelbergh RC. Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 2003;9:2583-6.
45. Poon RT, Fan ST, Wong J. Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches. Ann Surg 2003;238:9-28.
46. Zhang X, Yamashita M, Uetsuki H, Kakehi Y. Angiogenesis in renal cell carcinoma: evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases. Int J Urol 2002;9: 509-14.
47. de la Taille A, Katz AE, Bagiella E, Buttyan R, Sharir S, Olsson CA, Burchardt T, Ennis RD, Rubin MA. Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31. Am J Clin Pathol 2000;113:555-62.
48. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 2002;5:123-7.
49. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-9.
50. Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997;79:772-9.
51. Gettman MT, Bergstralh EJ, Blute M, Zincke H, Bostwick DG. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology 1998;51:79-85.
52. Rubin MA, Buyyounouski M, Bagiella E, Sharir S, Neugut A, Benson M, de la Taille A, Katz AE, Olsson CA, Ennis RD. Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 1999;53:542-7.
53. Tengblad A. Affinity chromatography on immobilized hyaluronate and its application to the isolation of hyaluronate binding properties from cartilage. Biochim Biophys Acta 1979;578:281-99.
54. Norrby K, Ridell B. Tumour-type-specific capillary endothelial cell stainability in malignant B-cell lymphomas using antibodies against CD31, CD34 and factor VIII. APMIS 2003;111:483-9.
55. Delpech B, Laquerriere A, Maingonnat C, Bertrand P, Freger P. Hyaluronidase is more elevated in human brain metastases than in primary brain tumours. Anticancer Res 2002;22:2423-7.
56. Hiltunen EL, Anttila M, Kultti A, Ropponen K, Penttinen J, Yliskoski M, Kuronen AT, Juhola M, Tammi R, Tammi M, Kosma VM. Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Cancer Res 2002;62:6410-3.
57. Jacobson A, Rahmanian M, Rubin K, Heldin P. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer 2002;102:212-9.
58. Patel S, Turner PR, Stubberfield C, Barry E, Rohlff CR, Stamps A, McKenzie E, Young K, Tyson K, Terrett J, Box G, Eccles S, Page MJ. Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer. Int J Cancer 2002;97:416-24.
59. Canto EI, Shariat SF, Slawin KM. Biochemical staging of prostate cancer. Urol Clin North Am 2003;30:263-77.